Silence Therapeutics plc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

SLN$19.79+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Balance Sheets

Consolidated balance sheets

	Year ended December 31,
Note · 2024 · 2023
Current assets
Cash and cash equivalents	11		$121,330		$68,789
Short-term investments		26,004		-
R&D benefit receivable		24,396		22,442
Other current assets	12		14,664		11,630
Trade receivables	13		972		290
Total current assets		187,366		103,151
Property, plant and equipment	8		1,818		1,938
Operating lease right-of-use assets	15		157		370
Goodwill	9		9,392		9,981
Other intangible assets	10		312		362
Other long-term assets	12		3,590		3,646
Total assets		$202,635		$119,448
Current liabilities
Contract liabilities	16		$(306)		$(6,571)
Trade and other payables	14		(16,399)		(15,537)
Operating lease liabilities, current	15		(117)		(228)
Total current liabilities		(16,822)		(22,336)
Contract liabilities	16		(51,790)		(75,001)
Operating lease liabilities, long-term	15		-		(118)
Total liabilities		$(68,612)		$(97,455)
Commitments and contingencies (Note 20)
Shareholders’ equity
Ordinary shares - par value £0.05 per share; 141,674,074 shares issued at December 31, 2024 (2023: 118,846,966)	18		(10,288)		(8,847)
Additional paid-in capital		(609,560)		(455,765)
Accumulated deficit		474,044		431,894
Accumulated other comprehensive loss		11,781		10,725
Total shareholders' equity		(134,023)		(21,993)
Total liabilities and shareholders' equity		$(202,635)		$(119,448)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.